Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNFα

[1]  H. Nishimura,et al.  IL-6 signal blockade ameliorates the enhanced osteoclastogenesis and the associated joint destruction in a novel FcγRIIB-deficient rheumatoid arthritis mouse model , 2015, Modern rheumatology.

[2]  R. Buchbinder,et al.  Comparative Effectiveness of Anti–Tumor Necrosis Factor Drugs on Health‐Related Quality of Life Among Patients With Inflammatory Arthritis , 2014, Arthritis care & research.

[3]  A. Skapenko,et al.  Decreased expression of miR-146a and miR-155 contributes to an abnormal Treg phenotype in patients with rheumatoid arthritis , 2014, Annals of the rheumatic diseases.

[4]  P. Voulgari,et al.  Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival. , 2014, Seminars in arthritis and rheumatism.

[5]  T. Grodzicki,et al.  Effect of tumour necrosis factor-α inhibitor on serum level of dickkopf-1 protein and bone morphogenetic protein-7 in ankylosing spondylitis patients with high disease activity , 2014, Scandinavian journal of rheumatology.

[6]  N. Bottini,et al.  Epigenetics in Rheumatoid Arthritis: A Primer for Rheumatologists , 2013, Current Rheumatology Reports.

[7]  A. Pivarcsi,et al.  Changes in the level of serum microRNAs in patients with psoriasis after antitumour necrosis factor‐α therapy , 2013, The British journal of dermatology.

[8]  H. Mann,et al.  Association of circulating miR-223 and miR-16 with disease activity in patients with early rheumatoid arthritis , 2013, Annals of the rheumatic diseases.

[9]  L. Essioux,et al.  The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure. , 2013, Rheumatology.

[10]  B. Jallal,et al.  microRNA-mediated regulation of innate immune response in rheumatic diseases , 2013, Arthritis Research & Therapy.

[11]  B. Roschitzki,et al.  Discovery of serum proteomic biomarkers for prediction of response to infliximab (a monoclonal anti-TNF antibody) treatment in rheumatoid arthritis: an exploratory analysis. , 2012, Journal of proteomics.

[12]  Wu-xian Li,et al.  Circulating microRNAs as candidate biomarkers in patients with systemic lupus erythematosus. , 2012, Translational research : the journal of laboratory and clinical medicine.

[13]  C. Rommel,et al.  PI3 kinase δ is a key regulator of synoviocyte function in rheumatoid arthritis. , 2012, The American journal of pathology.

[14]  A. Barton,et al.  Genetic and genomic predictors of anti-TNF response. , 2011, Pharmacogenomics.

[15]  E. Chan,et al.  MicroRNAs in systemic rheumatic diseases , 2011, Arthritis research & therapy.

[16]  M. Ochi,et al.  The inhibitory effect of microRNA-146a expression on bone destruction in collagen-induced arthritis. , 2011, Arthritis and rheumatism.

[17]  A. Eisenreich,et al.  PI3K inhibitors in cardiovascular disease. , 2011, Cardiovascular therapeutics.

[18]  N. Adachi,et al.  MicroRNA-146a expresses in interleukin-17 producing T cells in rheumatoid arthritis patients , 2010, BMC musculoskeletal disorders.

[19]  Takashi Nakamura,et al.  Plasma and synovial fluid microRNAs as potential biomarkers of rheumatoid arthritis and osteoarthritis , 2010, Arthritis research & therapy.

[20]  A. Mobasheri,et al.  Synergistic chondroprotective effects of curcumin and resveratrol in human articular chondrocytes: inhibition of IL-1β-induced NF-κB-mediated inflammation and apoptosis , 2009, Arthritis research & therapy.

[21]  P. Sarzi-Puttini,et al.  Anti-cytokine antibodies for rheumatic diseases. , 2009, Current opinion in investigational drugs.

[22]  M. Goldring,et al.  Cartilage homeostasis in health and rheumatic diseases , 2009, Arthritis research & therapy.

[23]  Masahiro Kurosaka,et al.  MicroRNA-124a is a key regulator of proliferation and monocyte chemoattractant protein 1 secretion in fibroblast-like synoviocytes from patients with rheumatoid arthritis. , 2009, Arthritis and rheumatism.

[24]  Peter Nightingale,et al.  Association of interleukin-6 (IL-6)-174G/C gene polymorphism with cardiovascular disease in patients with rheumatoid arthritis: the role of obesity and smoking. , 2009, Atherosclerosis.

[25]  A. Rubbert-Roth,et al.  Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review , 2009, Arthritis research & therapy.

[26]  Kaleb M. Pauley,et al.  MicroRNAs and Their Emerging Roles in Immunology , 2008, Annals of the New York Academy of Sciences.

[27]  Kaleb M. Pauley,et al.  Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients , 2008, Arthritis research & therapy.

[28]  Michael Detmar,et al.  Altered expression of MicroRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. , 2008, Arthritis and rheumatism.

[29]  R. Plenge,et al.  Genetic variants that predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis: current challenges and future directions , 2008, Current opinion in rheumatology.

[30]  F. Luyten,et al.  Contemporary concepts of inflammation, damage and repair in rheumatic diseases. , 2006, Best practice & research. Clinical rheumatology.

[31]  F. Luyten,et al.  Noggin haploinsufficiency differentially affects tissue responses in destructive and remodeling arthritis. , 2006, Arthritis and rheumatism.

[32]  M. Pfaffl,et al.  Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper – Excel-based tool using pair-wise correlations , 2004, Biotechnology Letters.

[33]  G. Panayi,et al.  Cytokine pathways and joint inflammation in rheumatoid arthritis. , 2001, The New England journal of medicine.

[34]  Kozo Nakamura,et al.  Fibroblast Growth Factor (FGF)-2 Directly Stimulates Mature Osteoclast Function through Activation of FGF Receptor 1 and p42/p44 MAP Kinase* , 2000, The Journal of Biological Chemistry.

[35]  A. Silman,et al.  UvA-DARE (Digital Academic Repository) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative Aletaha, , 2010 .

[36]  D B Young,et al.  IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. , 1997, Science.